On August 12, Daiichi Sankyo announced that the new indications for Uherd® have been approved in China. The approved indications are: This product in combination with pertuzumab is suitable for first-line treatment of unresectable or metastatic HER2-positive adult breast cancer patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.